The Scottish model of vancomycin dosing and therapeutic drug monitoring improves both efficacy and safety of vancomycin therapy

1. Martínková J. Současný náhled na vankomycin v léčbě infekcí vyvolaných stafylokokem rezistentním na methicilin (MRSA). Klini Mikrobiol Inf Lék 2015; 21(1): 16–23. 2. Sinha RA, Haikal A, Hammoud KA et al. Vancomycin and the Risk of AKI: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol 2016; 11(12): 2132–2140. Dostupné z DOI: . 3. Kacířová I, Grundmann M. TDM antibiotik v klinické praxi. Kardiol Rev Int Med 2015; 17(1): 57–64. 4. Štěpán M, Chytra M, Pelnář P et al. Kontinuální versus intermitentní podání vankomycinu u grampozitivních infekcí rezistentních na beta-laktamová antibiotika u nemocných v intenzivní péči. Anest intenziv Med 2009; 20(6): 309–316. 5. Brown ML, Hutchison AM, McAtee AM et al. Allometric versus consensus guideline dosing in achieving target vancomycin trough concentrations. Am J Health Syst Pharm 2017; 74(14):1067–1075. Dostupné z DOI: . 6. Tongsai S, Koomanachai P. The safety and efficacy of high versus low vancomycin trough levels in the treatment of patients with infections caused by methicillin-resistant Staphylococcus aureus: a meta-analysis. BMC Research Notes 2016; 9(1): 455. Dostupné z DOI: . 7. Kacířová I, Grundmann M. Terapeutické monitorování vankomycinu v rutinní klinické praxi. Vnitř Lék 2014; 60(10): 846–851. 8. Holmes NE, Turnidge JD, Munckhof WJ et al. Vancomycin AUC/MIC Ratio and 30-Day Mortality in Patients with Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother 2013; 57(4): 1654–1663. Dostupné z DOI: . 9. Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52(3): e18-e55. Dostupné z DOI: . 10. Bakke V, Sporsem H, Von der Lippe E et al. Vancomycin levels are frequently subtherapeutic in critically ill patients: a prospective observational study. Acta Anaesthesiol Scand 2017; 61(6): 627–635. Dostupné z DOI: . 11. Scottish Antimicrobial Prescribing Group Guidance. Dostupné z WWW: . 12. Chrdle A, Horníková M, Pešková M. Doporučený postup parenterálního dávkování vankomycinu v Nemocnici České Budějovice. Nemocnice České Budějovice, a.s. NCB_SOP_L_13_008_A, verze 1.7.2015. 13. Ploessl C, White C, Manasco K. Correlation of a Vancomycin Pharmacokinetic Model and Trough Serum Concentrations in Pediatric Patients. Pediatr Infect Dis J 2015; 34(10): e244-e247. Dostupné z DOI: . 14. Kishk OA, Lardieri AB, Heil EL et al. Vancomycin AUC/MIC and Corresponding Troughs in a Pediatric Population. J Pediatr Pharmacol Ther 2017; 22(1): 41–47. Dostupné z DOI: . 15. Rybak MJ, Lomaestro BM, Rotschafer JC et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2009; 29(11): 1275–1279. 16. Sutton JD, Mynatt RP, Kaye KS et al. Nephrotoxicity Comparison of Two Commercially Available Generic Vancomycin Products. Antimicrob Agents Chemother 2015; 59(9): 5470–5474. Dostupné z DOI: . 17. Pereira M, Rodrigues N, Godinho I et al. Acute kidney injury in patients with severe sepsis or septic shock: a comparison between the “Risk, Injury, Failure, Loss of kidney function, End-stage kidney disease” (RIFLE), Acute Kidney Injury Network (AKIN) and Kidney Disease: Improving Global Outcomes (KDIGO) classifications. Clin Kidney J 2017; 10(3): 332–340. Dostupné z DOI: . 18. Suchánková H, Machačová M, Herodesová T. Terapeutické monitorování vankomycinu v klinické praxi. Klin Farmakol Farm 2016; 30(2): 4–8. 19. Bond SE, Crowther SP, Adhikari S et al. Design and Implementation of a Novel Web-Based E-Learning Tool for Education of Health Professionals on the Antibiotic Vancomycin. J Med Internet Res 2017; 19(3): e93. Dostupné z DOI: .